

**MINUTE  
AREA DRUG AND THERAPEUTICS COMMITTEE  
WEDNESDAY 19<sup>th</sup> JAN @10am  
Microsoft Teams Meeting**

**In Attendance:**

Dr Mehrdad Malekian	Mrs Karen Patterson	Mrs Christine Gilmour
Dr Tyra Smyth	Mrs Emma Harris	Mrs Linda Johnstone
Mrs Penny Brankin	Mrs Carol McGoff	Dr Stephanie Dundas
Mrs Katrina Maroni	Mrs Gail Richardson	Mr George Lindsay
Dr Iain Hathorn		

		Action
2022/01	1. <b><u>Apologies for Absence</u></b> Dr David Semple, Mr Bill Angus. Mr John Milne	
2022/02	2. <b><u>Declaration of Interest</u></b>  There were no declarations of interest.	
2022/03	3. <b><u>Matters arising not covered elsewhere on the agenda</u></b>  a. <b><u>Ratification of minutes of meeting 15<sup>th</sup> December 2021</u></b>  The minute was accepted as an accurate record with a spelling correction to be made  The ADTC's opinion is that oxygen should best be prescribed on the MEWS chart.  to be changed to  The ADTC's opinion is that oxygen should best be prescribed on the NEWS chart.  b. <b><u>Dapagliflozin in Heart Failure ( Non Diabetic)</u></b>  This was agreed as finalised document and can now be published.	<b>GL</b>

	<p><b>c. <u>Oxygen Prescribing in Acute Settings</u></b></p> <p>Dr Malekian has discussed with Dr Keaney with the outcome that Dr Malekian will attend the Acute Governance Committee to take this matter to conclusion.</p> <p><b>d. <u>Steroid Emergency Cards</u></b></p> <p>This item will be carried over til the February meeting.</p> <p><b>e. <u>Ravulizumab</u></b></p> <p>The latest version has some formatting and typographical issues. Mr Lindsay will ask Mr Milne to update and reply to all members of the ADTC and Dr Mitchell with a request for comments by 31<sup>st</sup> January.</p>	<p><b>MM</b></p> <p><b>CG</b></p> <p><b>GL</b></p>
<p>2022/04 4.</p>	<p><b><u>SMC ADVICE</u></b></p> <p><b><u>FULL SUBMISSIONS</u></b></p> <p><b>Nivolumab (Opdivo®) SMC2385</b> This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).</p> <p><b>Cannabidiol (Epidyolex®) SMC2402</b> This was noted.</p> <p><b>Pemigatinib (Pemazyre®) SMC2399</b> This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).</p> <p><b>Enzalutamide (Xtandi®) SMC2400</b> This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).</p> <p><b>Risdiplam (Evryssi®) SMC2401</b> This was noted.</p> <p><b>Cenobamate (Ontozry®) SMC2408</b> This was noted and will be referred to neurology specialists.</p> <p><b><u>AMENDED ADVICE</u></b></p> <p><b>Trastuzumab deruxtecan (Enhertu®) SMC2388</b> This was noted.</p> <p><b><u>UPDATE ON THE INTERIM ASSESSMENT APPROACH IN RESPONSE TO COVID-19</u></b> This is a pragmatic approach to minimise delay in patient access as a result of the COVID-19 pandemic. Following review by the SMC executive, SMC advice for the submission noted below will be published on the SMC website on Monday 07 February 2022.</p>	

	<p><b><u>ABBREVIATED SUBMISSION</u></b></p> <p><b>Diroximel fumarate (Vumerity®) SMC2444</b> This was noted.</p> <p><b><u>PAEDIATRIC LICENCE EXTENSIONS</u></b> This was noted.</p>	
2022/05	<p><b>5. <u>SMC follow up</u></b></p> <p>Mrs Maroni talked the committee through the SMC follow up which had been previously circulated. Feedback on a number of items is expected in due course.</p>	
2022/06	<p><b>6. <u>Lanarkshire Formulary</u></b></p> <p>Mrs McGoff proposed three formulary amendments. The first was the addition of empagliflozin to the SGLT2 inhibitors for heart failure section of the formulary, following the ratification of the 'Management of Patients with Heart Failure-Reduced Ejection Fraction (HFrEF)' guideline under item 3(b) above.</p> <p>The second was the addition of a weblink to the Specialist Pharmacy Service website, which gives advice on the prescribing and administration of CosmoFer®. The link will be added to the parenteral iron section in Chapter 9.</p> <p>The third and final amendment pertained to the removal of Psoriderm® emulsion which has been discontinued, with the proposal to replace with Psoriderm® cream. Dermatology were consulted and agreed with this substitution. The Committee approved all of the above.</p>	
2022/07	<p><b>7. <u>Clinical Protocols</u></b></p> <p>There was nil to report at this today's meeting.</p>	
2022/08	<p><b>8. <u>ADTC New Medicines Decisions</u></b></p> <p>This was noted.</p>	<b>KM</b>
2022/09	<p><b>9. <u>Unlicensed Medicines</u></b></p> <p>It was noted that the use of Remdesivir for hospitalised patients in line with national guidance had been signed off by clinical bronze.</p>	
2022/10	<p><b>10. <u>Patient Group Directions</u></b></p> <p>There was nil to report at this today's meeting.</p>	

2022/11 11.	<p><b><u>Medication and Clinical risk in Lanarkshire</u></b>  <a href="https://www.gov.uk/drug-safety-update">https://www.gov.uk/drug-safety-update</a></p> <p>This was noted.</p> <p>Mrs Brankin drew attention to the supply of Emerade and there was wider discussion about experience gained these past few years with disruption to adrenaline auto injectors.</p>	
2022/12 12.	<p><b><u>Regional Cancer Advisory Network</u></b></p> <p>There was nil to report at this today's meeting.</p>	
2022/13 13.	<p><b><u>Patient Safety Alerts</u></b></p> <p>There was nil to report at this today's meeting.</p>	
2022/14 14.	<p><b><u>Lay member related items</u></b></p> <p>There was nil to report at this today's meeting.</p>	
2022/15 15.	<p><b><u>Correspondence</u></b></p> <p><b><u>Chronic Pain</u></b></p> <p>There was a useful debate about the value of comparing our local document with the SG document when finalised and actively promoting the key issues. This is most likely to be carried out by the Chronic Pain Specialist Interest Group.</p>	
2022/16 16.	<p><b><u>Pharmacy &amp; NMAHP Prescribing Governance</u></b></p> <p>Mrs Brankin gave a summary of the key points discussed including plans for PGDs and the initiation of a working group to review governance for prescribers joining NHS Lanarkshire from other Health Boards. Mrs Gilmour commented on the importance of a broad membership for that group.</p>	<b>PB</b>
2022/17 17.	<p><b><u>AOCB</u></b></p> <p>There was nil to report at this today's meeting.</p>	
2022/18 18.	<p><b><u>Date of next meeting</u></b></p> <p>Wednesday 16<sup>th</sup> February 2022 10am @ Microsoft Teams</p>	